Biotech Values

[poorgradstudent]

Drug Pricing:

The strange irony is, despite the current upheaval, I thought the system was largely working the way I'd like it to. I've posted here before that I'm supportive of pricing power for efficacious drugs because, in the long term, society pays an upfront price for a long term benefits. I consider the eventual availability of generics as the commensurate benefit in exchange for the run of relatively higher priced branded drugs.

Case in point, I think the "outrage" over Gilead's pricing of HCV drugs is just shortsighted folly. In the long run, this is a small price to pay for the societal benefit.

Sadly, Shkreli's intention of abusing the system (yeah I said it) now has people focused with the aim of reacting rather than properly assessing. I hope we can get over this bump without adversely impacting the sector in the long run.